Saneca Pharma gets bigger by going smaller, expands small batch production

Spotlight

Saneca Pharmaceuticals, a Slovakia-based CDMO that specializes in opiate APIs, is getting bigger with small batch API production.

The Hlohovec-based company said this week that it is expanding its suite of equipment within its 5 API production units to reinforce its opiate and synthetic drug development and production. It is adding several smaller reactors that will make it possible to produce batches as small as 1 kg to 30 kg in a new lab that can simulate large-scale production processes.

A spokesperson for the company said Saneca is investing €3.5 million ($3.9 million) and expects to add 5 employees as a result.  

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

While it is a modest investment by Big Pharma standards, it s a big deal for Saneca. “This is a very exciting time for our business,” Saneca CEO Anthony Sheehan said in a statement. He said the new capabilities will allow the site to handle work from phase III development to pilot plant to commercial production.

Saneca operates from a site that has been making APIs for 75 years. The company last year did try to expand production beyond Slovakia when it acquired Suir Pharma, a small and struggling CMO in County Tipperary, Ireland but the deal didn't work out. 

The two-plant operation had been sold by Germany’s Stada in 2012 to German restructuring specialist Mutares. Mutares then sold it for an undisclosed amount last year to Saneca but the Slovakian CDMO decided to put it into liquidation when losses at the facility continued to mount. Suir had reportedly run into problems with a Chinese API that prevented it from manufacturing a key product, running up $7.2 million (€4.9 million) in losses in 15 months. About 130 workers lost their jobs when Saneca decided to pull the plug on the operation.

- here’s the release

Related Articles:
Irish CMO in bankruptcy after Saneca Pharmaceuticals gives up on it
AMRI, Saneca Pharma team to produce a range of opium-based APIs

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.